Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26512477 | 0.84 | RAB9A (0.34) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL26512466 | 0.84 | — | — | |
| SCHEMBL26512471 | 0.83 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL26512483 | 0.83 | KDM4A (0.30) | RAB9A | |
| SCHEMBL26514216 | 0.83 | — | — | |
| SCHEMBL26512473 | 0.79 | — | — | |
| SCHEMBL25291704 | 0.77 | RAB9A (0.36) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL26512512 | 0.74 | KMT2A (0.32) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL26123852 | 0.74 | KMT2A (0.32) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL26512373 | 0.72 | KMT2A (0.33) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | UNIV COPENHAGEN (DK) | 2023-10-12 | — | — | US | disclosed |
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | UNIV COPENHAGEN (DK) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321043-A1 | COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES | GMPS, PDE11A, CGAS | NPC1 4210/4885RAB9A 1963/4885SMN1; SMN2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.